Market Cap 620.51B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 23.95
Forward PE 22.19
Profit Margin 28.46%
Debt to Equity Ratio 0.46
Volume 10,545,204
Avg Vol 8,142,826
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 15%
Beta 0.24
Analysts Strong Sell
Price Target $262.56

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
Millionaire11
Millionaire11 Jul. 15 at 10:59 PM
$CMPS - $ATAI buy out from $LLY that means $JNJ could still be eying $CMPS. Lets hope for a massive buy out price of 10 billion plus. That would be massive for the whole industry. Good luck every body and trust the process.
1 · Reply
MichaelNaussCMT
MichaelNaussCMT Jul. 15 at 9:02 PM
$ATAI $CMPS $DFTX $HELP $JNJ price action tells you this a long time ago
0 · Reply
Bazziggr
Bazziggr Jul. 15 at 8:57 PM
$JNJ BSX
0 · Reply
UltimateTrader_22
UltimateTrader_22 Jul. 15 at 6:51 PM
$AIMN The right network. The right context. @AimwellBIO Observer connects serious healthcare professionals to trusted signals, curated intelligence, and a verified network built for the future of healthcare. Apply free. Stay in the network. http://aimwellbio.com/observer-signup $AIMN #pharma $PFE $JNJ $MEDI
0 · Reply
Jack90
Jack90 Jul. 15 at 6:47 PM
Loading $PFE, $BMY, $JNJ
0 · Reply
musicalchairsponzi
musicalchairsponzi Jul. 15 at 6:25 PM
$JNJ is this an AI company? Why is it up like 80% in the last year lol
0 · Reply
khalidsa
khalidsa Jul. 15 at 5:51 PM
$JNJ I hope to enter the baby diaper manufacturing business soon; maybe things will improve a little. 🥸
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 15 at 5:25 PM
0 · Reply
theoptionsplug
theoptionsplug Jul. 15 at 5:17 PM
$JNJ testing its previous resistance area as support! Earning report shows a raise for its full-year guidance after reporting second-quarter adjusted earnings of $2.90 a share! The company’s quarterly sales rise 6% from the same period last year to $25 billion Respected $250 will set up a BEAUTIFUL move!
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 15 at 5:04 PM
$DJT $JNJ $PFE $MRNA $LLY Let me share a little secret with you..... This is why ELTP is going to be Big..... Their Technology will save the world... Look it up/ Here are the two people who are backing ELTP.
1 · Reply
Latest News on JNJ
Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 10 hours ago

Johnson & Johnson Earnings Call Transcript: Q2 2026


Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 10 hours ago

Johnson & Johnson Slides: Q2 2026


Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 10 hours ago

Johnson & Johnson Earnings release: Q2 2026


Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:35 AM EDT - 12 hours ago

Johnson & Johnson Hikes Guidance, Stock Falls


Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:33 AM EDT - 12 hours ago

Johnson & Johnson Bumps Up Guidance as Sales Rise


Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Jul 15, 2026, 6:20 AM EDT - 13 hours ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook


The Big 3: UNH, KO, JNJ

Jul 9, 2026, 1:00 PM EDT - 6 days ago

The Big 3: UNH, KO, JNJ

KO UNH


Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 9:01 AM EDT - 5 weeks ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion


Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:08 AM EDT - 5 weeks ago

Johnson & Johnson to buy Firefly Bio for $1 billion


Johnson & Johnson says nipocalimab approved in China

May 21, 2026, 4:31 AM EDT - 7 weeks ago

Johnson & Johnson says nipocalimab approved in China


CVS to drop J&J's Stelara from its main formularies

May 5, 2026, 9:15 AM EDT - 2 months ago

CVS to drop J&J's Stelara from its main formularies

CVS


Millionaire11
Millionaire11 Jul. 15 at 10:59 PM
$CMPS - $ATAI buy out from $LLY that means $JNJ could still be eying $CMPS. Lets hope for a massive buy out price of 10 billion plus. That would be massive for the whole industry. Good luck every body and trust the process.
1 · Reply
MichaelNaussCMT
MichaelNaussCMT Jul. 15 at 9:02 PM
$ATAI $CMPS $DFTX $HELP $JNJ price action tells you this a long time ago
0 · Reply
Bazziggr
Bazziggr Jul. 15 at 8:57 PM
$JNJ BSX
0 · Reply
UltimateTrader_22
UltimateTrader_22 Jul. 15 at 6:51 PM
$AIMN The right network. The right context. @AimwellBIO Observer connects serious healthcare professionals to trusted signals, curated intelligence, and a verified network built for the future of healthcare. Apply free. Stay in the network. http://aimwellbio.com/observer-signup $AIMN #pharma $PFE $JNJ $MEDI
0 · Reply
Jack90
Jack90 Jul. 15 at 6:47 PM
Loading $PFE, $BMY, $JNJ
0 · Reply
musicalchairsponzi
musicalchairsponzi Jul. 15 at 6:25 PM
$JNJ is this an AI company? Why is it up like 80% in the last year lol
0 · Reply
khalidsa
khalidsa Jul. 15 at 5:51 PM
$JNJ I hope to enter the baby diaper manufacturing business soon; maybe things will improve a little. 🥸
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 15 at 5:25 PM
0 · Reply
theoptionsplug
theoptionsplug Jul. 15 at 5:17 PM
$JNJ testing its previous resistance area as support! Earning report shows a raise for its full-year guidance after reporting second-quarter adjusted earnings of $2.90 a share! The company’s quarterly sales rise 6% from the same period last year to $25 billion Respected $250 will set up a BEAUTIFUL move!
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 15 at 5:04 PM
$DJT $JNJ $PFE $MRNA $LLY Let me share a little secret with you..... This is why ELTP is going to be Big..... Their Technology will save the world... Look it up/ Here are the two people who are backing ELTP.
1 · Reply
Suite510
Suite510 Jul. 15 at 5:01 PM
$JNJ $KVUE JNJ shares fall too, med tech earnings miss and huge Talc and Tylenol legal risks, that’s perfect medicine for them 🤣🙈
1 · Reply
DidYouReadThis
DidYouReadThis Jul. 15 at 4:36 PM
$OTLK 2 weeks before 7/29/26 #PDUFA… Bottom Bollinger looks like 1.40? How many more more super sales, can it drop under 1.40, with a little help from some stop losses, or shorts? #stillLONG $REGN $PFE $JNJ
0 · Reply
parcha
parcha Jul. 15 at 4:21 PM
Jim Cramer's top 10 things to watch in the stock market Wednesday $JNJ $XLV Club name Johnson & Johnson delivered a beat-and-raise this morning, though the stock is down 2%. Tremfya, one of its key growth drugs, topped expectations. There was some weakness on the medical-device side, specifically within cardiology. Not ideal, but I am confident they can fix the problem. Could be a chance to buy once the dust settles on the quarter. https://www.cnbc.com/2026/07/15/jim-cramers-top-10-things-to-watch-in-the-stock-market-wednesday.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
chuckieclam
chuckieclam Jul. 15 at 4:15 PM
0 · Reply
robcarroll
robcarroll Jul. 15 at 4:01 PM
$JNJ has the firepower ($101B revenue, actively acquiring), plays in blood cancers, and $SLS WT1 platform fits their oncology build-out. Not the most obvious buyer — AbbVie, Pfizer, Novartis fit better — but absolutely capable of doing a $30-40B deal. Don't rule them out. https://qz.com/johnson-johnson-q2-2026-earnings-medicines-outlook-071526
1 · Reply
briefingcom
briefingcom Jul. 15 at 3:16 PM
$JNJ: Johnson & Johnson delivered a strong Q2, raised FY26 EPS and revenue guidance, and remains on track to surpass $100 bln in annual revenue for the first time. Innovative Medicine remains the growth engine, while MedTech and Abiomed are the main watch items. See full analysis: https://www.briefing.com/story-stocks/archive/2026/7/15/johnson--and--johnson-reports-healthy-q2-but-medtech-a-bit-soft?utm_campaign=storystocks&utm_medium=social&utm_source=st&utm_content=link #JNJ #earnings #guidance #medtech #medicine #Abiomed #healthcare
0 · Reply
Arandkei
Arandkei Jul. 15 at 3:12 PM
$JNJ — In Q1, management called Impella ECP a growth driver "not yet fully reflected in consensus models" and Abiomed posted 14.4% growth with an evidence base described as "absolutely solid." This quarter: Abiomed declined 2%, driven by a neutral U.K. clinical trial on high-risk PCI increasing physician selectivity. Schmid: "our Q2 growth is not where you wanted it, and frankly, it's not where we wanted it." Recovery expected "probably as we leave this year into next year," with PROTECT IV (1,300 patients) reading out in 2027. On the other side: TREMFYA hit its first $2B quarter at 71% growth, ICOTYDE launched with 18,000 prescriptions and 50%+ formulary coverage in 90 days, and guidance moved from $100.2B to $100.6B. #TheGapReport
0 · Reply
Bazziggr
Bazziggr Jul. 15 at 2:38 PM
$JNJ UTHR
0 · Reply
spearnreel
spearnreel Jul. 15 at 2:10 PM
$BSX You’ll never beat “them” but have full right to always join “them”. Yesterday’s hit piece capitulation games across the entire med tech sector should serve as buy indicator imo. $43’s today to solidify how these games are played. Blueprint for trading moving forward. $JNJ $ISRG $ABT
0 · Reply
khalidsa
khalidsa Jul. 15 at 2:06 PM
$JNJ rip this markt is trash 🗑️
0 · Reply
EarningsInsider
EarningsInsider Jul. 15 at 2:00 PM
https://www.marketbeat.com/earnings/reports/2026-7-15-johnson-johnson-stock/ $JNJ Johnson & Johnson Earnings Transcript
0 · Reply
Monludo06
Monludo06 Jul. 15 at 1:54 PM
$SLS Hmm... good results and potential acquisitions... that rings a bell. $JNJ
1 · Reply